FDA final guidance sets a risk-based potency assurance roadmap for cell and gene therapies, spanning development, ...

Sail Biomedicine’s $925 million deal with Johnson & Johnson helped boost the cell and gene therapy sector over biologics in ...

As CAR-T therapies continue to evolve, improved care coordination, earlier patient referrals and enhanced support systems can ...

An experimental treatment has kept one patient with heavily pretreated hairy cell leukemia free of detectable disease for ...

IASO Bio and its Singapore partner Pills and Pokes jointly hosted the FUCASO launch event in Singapore on November 3, marking the official commercial ...

As transplantation and cellular therapy continue to evolve, reducing treatment-related toxicities remains one of the field's ...

Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, has joined with 40 other centers in the U.S. and Europe as a site in one of the first clinical trials ...

Global market projected to expand from USD 8.94 billion in 2025 to USD 10.44 billion in 2026, registering an 18.1% CAGR ...

Patients who develop cytokine release syndrome after chimeric antigen receptor T-cell therapy for autoimmune disease ...

Oct 27 (Reuters) - Artiva Biotherapeutics said on Tuesday it would halt the development of an experimental cell therapy for certain autoimmune conditions — its lead candidate — after two patient ...

The investigators report that the phase 1 portion of the COMPARE trial met its safety end point and cleared the study to ...

Serum-free cell culture market grows from USD 4.66 Billion in 2026 to USD 7.76 Billion by 2030, driven by cell and gene therapy commercialization, biologics capacity and chemically defined, xeno-free ...